钩虫治疗复发型多发性硬化:随机双盲安慰剂对照试验
该9个月双盲随机安慰剂对照试验在诺丁汉大学医院招募71例未接受疾病修饰治疗的复发型MS患者,1:1分配接受25条美洲钩虫幼虫经皮或安慰剂。
要点
- 钩虫治疗未显著减少MS的MRI病灶累计数,可能因疾病活动度低。
- 钩虫感染可升高外周血CD4+CD25highCD127neg调节性T细胞百分比。
- 钩虫组复发5例(14.3%),安慰剂组11例(30.6%),安全性良好。
核心结论
- 钩虫治疗安全且耐受良好,主要终点未达显著性,但调节性T细胞增加提示免疫调节效应。
研究设计与样本
- 9个月双盲随机安慰剂对照试验,在单一三级转诊中心进行,改良意向性分析人群共71例复发型MS患者。
主要发现
- 第9个月新发/扩大/增强病灶累计数两组无显著差异,钩虫组零活动MRI比例51.4%(18/35)vs 安慰剂组27.8%(10/36)。
- 钩虫组复发5例(14.3%),安慰剂组11例(30.6%);除应用部位皮肤不适(82% vs 28%)外不良事件无差异。
关键数值与推荐
- 主要终点为第9个月新发/扩大T2或新增强T1病灶累计数,采用预设Mann-Whitney U检验。
- 次要终点为外周血CD4+CD25highCD127negT调节细胞百分比。
临床怎么用
- 钩虫治疗未显著改善MRI活动度,暂不支持作为复发型MS的常规治疗。
- 调节性T细胞升高提示活体生物可诱发免疫调节变化,值得进一步研究。
局限性
- 主要终点未达显著性,可能因疾病活动度低导致统计效力不足。
- Mann-Whitney U检验在数据结值多时效力降低。
- 单中心研究,样本量有限,随访9个月。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Studies suggest gut worms induce immune responses that can protect against multiple sclerosis (MS). To our knowledge, there are no controlled treatment trials with helminth in MS. OBJECTIVE: To determine whether hookworm treatment has effects on magnetic resonance imaging (MRI) activity and T regulatory cells in relapsing MS. DESIGN, SETTING, AND PARTICIPANTS: This 9-month double-blind, randomized, placebo-controlled trial was conducted between September 2012 and March 2016 in a modified intention-to-treat population (the data were analyzed June 2018) at the University of Nottingham, Queen's Medical Centre, a single tertiary referral center. Patients aged 18 to 61 years with relapsing MS without disease-modifying treatment were recruited from the MS clinic. Seventy-three patients were screened; of these, 71 were recruited (2 ineligible/declined). INTERVENTIONS: Patients were randomized (1:1) to receive either 25 Necator americanus larvae transcutaneously or placebo. The MRI scans were performed monthly during months 3 to 9 and 3 months posttreatment. MAIN OUTCOMES AND MEASURES: The primary end point was the cumulative number of new/enlarging T2/new enhancing T1 lesions at month 9. The secondary end point was the percentage of cluster of differentiation (CD) 4+CD25highCD127negT regulatory cells in peripheral blood. RESULTS: Patients (mean [SD] age, 45 [9.5] years; 50 women [71%]) were randomized to receive hookworm (35 [49.3%]) or placebo (36 [50.7%]). Sixty-six patients (93.0%) completed the trial. The median cumulative numbers of new/enlarging/enhancing lesions were not significantly different between the groups by preplanned Mann-Whitney U tests, which lose power with tied data (high number of zeroactivity MRIs in the hookworm group, 18/35 [51.4%] vs 10/36 [27.8%] in the placebo group). The percentage of CD4+CD25highCD127negT cells increased at month 9 in the hookworm group (hookworm, 32 [4.4%]; placebo, 34 [3.9%]; P = .01). No patients withdrew because of adverse effects. There were no differences in adverse events between groups except more application-site skin discomfort in the hookworm group (82% vs 28%). There were 5 relapses (14.3%) in the hookworm group vs 11 (30.6%) receiving placebo. CONCLUSIONS AND RELEVANCE: Treatment with hookworm was safe and well tolerated. The primary outcome did not reach significance, likely because of a low level of disease activity. Hookworm infection increased T regulatory cells, suggesting an immunobiological effect of hookworm. It appears that a living organism can precipitate immunoregulatory changes that may affect MS disease activity. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01470521.
引用
- Tanasescu R, Tench CR, Constantinescu CS, et al. Hookworm Treatment for Relapsing Multiple Sclerosis: A Randomized Double-Blinded Placebo-Controlled Trial. JAMA Neurol. 2020. PMID: 32539079. doi:10.1001/jamaneurol.2020.1118
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。